Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 879

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 879
---
|:--|----------:|:--|:--|
| Basic:                                             | ​ | ​ | ​                       | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ |
| Weighted average common shares outstanding         | ​ | ​ | ​                       | ​ | 4,512,422 | ​ | ​ | ​ | ​    | ​ | 4,471,130 | ​ | ​ | ​ | ​    | ​ | 4,226,564 | ​ | ​ |
| Diluted:                                           | ​ | ​ | ​                       | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ |
| Weighted average common shares outstanding – Basic | ​ | ​ | ​                       | ​ | 4,512,422 | ​ | ​ | ​ | ​    | ​ | 4,471,130 | ​ | ​ | ​ | ​    | ​ | 4,226,564 | ​ | ​ |
| Common stock equivalents*                          | ​ | ​ | ​                       | ​ |         — | ​ | ​ | ​ | ​    | ​ |         — | ​ | ​ | ​ | ​    | ​ |         — | ​ | ​ |
| Denominator for diluted net loss per share         | ​ | ​ | ​                       | ​ | 4,512,422 | ​ | ​ | ​ | ​    | ​ | 4,471,130 | ​ | ​ | ​ | ​    | ​ | 4,226,564 | ​ | ​ |

* For the years ended December 31, 2023, 2022 and 2021, no amounts were considered common stock equivalents as their effects would have been anti-dilutive due to net losses for those periods. Basic and diluted net loss per share is computed as follows:

| ​                                           
 ​                                           | ​ 
 ​ | ​ 
 ​ | Year Ended December 31, 
 2023                    |   |           |   | ​ | ​ | 2022 |   |           |   | ​ | ​ | 2021 |   |           |   | ​ 
 ​ |
|:--------------------------------------------|:--|:--|:------------------------|:--|----------:|:--|